Key Highlights

  • Net loss was USD 53.95 million, or USD 0.36 per share, against an estimate of USD 0.41 per share.
  • Research and development expenses were USD 43.6 million and general and administrative expenses were USD 14.06 million.
  • Cash, cash equivalents and available-for-sale securities were USD 348.9 million at September 30, with no outstanding debt.
  • An FDA Type C meeting on a potential Accelerated Approval pathway for SGT-003 is scheduled for late fourth quarter.

Solid Biosciences (NASDAQ:SLDB) used its third quarter report to point to a regulatory meeting scheduled late in the fourth quarter of 2026. The company plans to discuss the preliminary INSPIRE DUCHENNE data package for its Duchenne muscular dystrophy gene therapy SGT-003 with the FDA and to seek guidance on a potential accelerated approval pathway. The company reported no revenue.

The Quarter in Reported Figures

The net loss was USD 53.95 million, or USD 0.36 per share, against USD 45.78 million, or USD 0.48 per share, in the third quarter of 2025. The EPS estimate was a loss of USD 0.41. Total operating expenses were USD 57.66 million against USD 48.06 million.

Research and development expenses were USD 43.6 million and general and administrative expenses were USD 14.06 million against USD 9.20 million. For nine months, the net loss was USD 165.48 million, or USD 1.23 per share, against USD 124.54 million, or USD 1.46 per share. Research and Development expenses for nine months were USD 134.0 million, against USD 102.2 million, which the company tied mainly to a USD 27.9 million increase in SGT-003 Manufacturing and clinical costs.

Pipeline Milestones and Safety Updates

SGT-003 has been dosed in 53 participants in the Phase 1/2 INSPIRE DUCHENNE trial as of November 3, 2026, and management described it as generally well tolerated, with two previously disclosed treatment-related serious adverse events. The Phase 3 IMPACT DUCHENNE trial began screening in October 2025, and in February 2026 the company announced alignment with the FDA on its design, including a primary endpoint of change from baseline in Time to Rise velocity at 18 months. Process performance qualification manufacturing batches are scheduled to be completed by the end of 2026.

In Friedreich's ataxia, five participants have been dosed in the Phase 1b FALCON trial of SGT-212, which management said has been well tolerated with no treatment-related serious adverse events. Management named the first quarter of 2027 for initial data, subject to enrollment. For SGT-501 in CPVT, management named dosing of the first participant in the ARTEMIS trial by the end of 2026 and initial safety data in the first half of 2027.

Cash, Financing and Runway

Cash, cash equivalents and available-for-sale securities were USD 348.9 million at September 30, excluding USD 1.3 million of restricted cash, with no outstanding debt. Cash used in Operating Activities was USD 145.36 million for nine months, against USD 102.73 million. Management said the balance is sufficient to fund operating expenses and capital expenditures for at least twelve months from the date of issuance of the financial statements.

The company raised approximately USD 226.3 million of net proceeds in a March 2026 private Placement of 14,973,257 shares at USD 5.61 per share plus pre-funded warrants. Under its at-the-market agreement, it sold 2,012,500 shares in the quarter for net proceeds of USD 15.7 million, and an August 2026 prospectus supplement covers sales of up to USD 200.0 million.

Key Figures Side by Side

A net loss of USD 53.95 million sits alongside cash and securities of USD 348.9 million, research and development expenses of USD 43.6 million and nine-month operating cash use of USD 145.36 million. Management named a late fourth quarter 2026 FDA meeting and first ARTEMIS dosing by the end of 2026, then FALCON data in the first quarter of 2027 and ARTEMIS safety data in the first half of 2027.